Trial: 202103238

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleuel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma

Phase

I

Principal Investigator

Ghobadi, Armin

Disease Site

Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov